- Home
- VTEX vs TNGX Comparison
VTEX vs TNGX Comparison
Compare VTEX & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTEX
- TNGX
- Stock Information
- Founded
- VTEX 1999
- TNGX 2014
- Country
- VTEX Cayman Islands
- TNGX United States
- Employees
- VTEX N/A
- TNGX N/A
- Industry
- VTEX Computer Software: Prepackaged Software
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- VTEX Technology
- TNGX Health Care
- Exchange
- VTEX Nasdaq
- TNGX Nasdaq
- Market Cap
- VTEX 791.5M
- TNGX 723.2M
- IPO Year
- VTEX 2021
- TNGX N/A
- Fundamental
- Price
- VTEX $4.42
- TNGX $7.86
- Analyst Decision
- VTEX Strong Buy
- TNGX Strong Buy
- Analyst Count
- VTEX 5
- TNGX 6
- Target Price
- VTEX $7.16
- TNGX $10.80
- AVG Volume (30 Days)
- VTEX 1.1M
- TNGX 4.1M
- Earning Date
- VTEX 11-06-2025
- TNGX 11-04-2025
- Dividend Yield
- VTEX N/A
- TNGX N/A
- EPS Growth
- VTEX 48.79
- TNGX N/A
- EPS
- VTEX 0.05
- TNGX N/A
- Revenue
- VTEX $230,497,000.00
- TNGX $24,296,000.00
- Revenue This Year
- VTEX $9.30
- TNGX $20.42
- Revenue Next Year
- VTEX $13.22
- TNGX N/A
- P/E Ratio
- VTEX $86.12
- TNGX N/A
- Revenue Growth
- VTEX 4.53
- TNGX N/A
- 52 Week Low
- VTEX $3.92
- TNGX $1.03
- 52 Week High
- VTEX $6.97
- TNGX $9.70
- Technical
- Relative Strength Index (RSI)
- VTEX 51.99
- TNGX 50.38
- Support Level
- VTEX $4.28
- TNGX $7.12
- Resistance Level
- VTEX $4.51
- TNGX $8.35
- Average True Range (ATR)
- VTEX 0.14
- TNGX 0.66
- MACD
- VTEX 0.02
- TNGX -0.10
- Stochastic Oscillator
- VTEX 67.02
- TNGX 44.35
About VTEX VTEX
Vtex provides a software-as-a-service digital commerce platform for enterprise brands and retailers. Its platform enables customers to execute their commerce plan, including building online stores, integrating and managing orders across channels, and creating marketplaces to sell products from third-party vendors. It generates maximum revenues from Brazil followed by Latin America and the rest of the world.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.